JP2011520781A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520781A5
JP2011520781A5 JP2011503360A JP2011503360A JP2011520781A5 JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5 JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5
Authority
JP
Japan
Prior art keywords
cell
egf
ms4a12
activity
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011503360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520781A (ja
Filing date
Publication date
Priority claimed from EP08007109A external-priority patent/EP2108701A1/en
Application filed filed Critical
Publication of JP2011520781A publication Critical patent/JP2011520781A/ja
Publication of JP2011520781A5 publication Critical patent/JP2011520781A5/ja
Pending legal-status Critical Current

Links

JP2011503360A 2008-04-10 2009-03-30 治療、診断及び検査のためのｍｓ４ａ１２を伴う方法、及びｍｓ４ａ１２を標的とする剤 Pending JP2011520781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08007109.5 2008-04-10
EP08007109A EP2108701A1 (en) 2008-04-10 2008-04-10 Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
PCT/EP2009/002309 WO2009124670A1 (en) 2008-04-10 2009-03-30 Methods involving ms4a12 and agents targeting ms4a12 for therapy, diagnosis and testing

Publications (2)

Publication Number Publication Date
JP2011520781A JP2011520781A (ja) 2011-07-21
JP2011520781A5 true JP2011520781A5 (https=) 2012-05-24

Family

ID=39811474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503360A Pending JP2011520781A (ja) 2008-04-10 2009-03-30 治療、診断及び検査のためのｍｓ４ａ１２を伴う方法、及びｍｓ４ａ１２を標的とする剤

Country Status (8)

Country Link
US (1) US20110027297A1 (https=)
EP (2) EP2108701A1 (https=)
JP (1) JP2011520781A (https=)
CN (1) CN101998992A (https=)
AU (1) AU2009235746A1 (https=)
CA (1) CA2714997A1 (https=)
NZ (1) NZ588177A (https=)
WO (1) WO2009124670A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2979792C (en) * 2015-02-24 2023-04-04 Gene Techno Science Co., Ltd. Method for diagnosing, preventing and treating cancer brain metastasis, and drug delivery system for enabling passage through blood-brain barrier
CN109562379A (zh) 2016-06-20 2019-04-02 拜克门寇尔特公司 用于染料共轭试剂的干燥过程
CN112204050B (zh) 2018-01-31 2025-03-14 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
MX2022001260A (es) * 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung

Similar Documents

Publication Publication Date Title
Zhao et al. SNHG12 promotes angiogenesis following ischemic stroke via regulating miR-150/VEGF pathway
Guo et al. Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application
Li et al. Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure
Shen et al. Post‐transcriptional regulation of the tumor suppressor miR‐139‐5p and a network of miR‐139‐5p‐mediated m RNA interactions in colorectal cancer
Pathak et al. Role of angiogenesis and its biomarkers in development of targeted tumor therapies
Wang et al. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma
Yao et al. Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1
Choi et al. Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration
Matsumoto et al. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma
Guo et al. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A
Baumann et al. Feed‐forward loops between metastatic cancer cells and their microenvironment—the stage of escalation
JP2014526456A5 (https=)
EP3111937A1 (en) Medicament for treatment of liver cancer
JP2016540778A5 (https=)
Zhu et al. eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma
Han et al. TUG1 is involved in liver fibrosis and activation of HSCs by regulating miR-29b
CA2946407A1 (en) Multiple targeted rnai for the treatment of cancers
Wang et al. Human cancer cells suppress behaviors of endothelial progenitor cells through miR-21 targeting IL6R
JP2014526450A5 (https=)
Zhang et al. Circ‐ACAP2 facilitates the progression of colorectal cancer through mediating miR‐143‐3p/FZD4 axis
EP3301176B1 (en) Method for identifying nucleic acids regulating metastasation
JP2011520781A5 (https=)
Wang et al. Long noncoding RNA LINC01426 promotes glioma progression through PI3K/AKT signaling pathway and serves as a prognostic biomarker.
Takiguchi et al. Involvement of CXCL14 in osteolytic bone metastasis from lung cancer
JP2014523398A5 (https=)